Combining αGITR antibodies with ICBs resulted in stronger survival benefits in mouse models of human glioblastoma brain cancer. Read More
Glioblastoma can mimic the normal repair of white matter in the brain, causing the tumor to become less malignant. Additionally, a drug commonly prescribed for asthma can help suppress glioblastoma growth in mouse models. Read More
A newly developed ion pump can deliver cancer-fighting drugs more accurately, and with fewer side effects than conventional chemotherapy, to those with glioblastoma brain cancer. Read More
Administering the chemotherapy drug temozolomide to glioblastoma brain cancer patients in the morning may enhance the cancer-fighting effects. The study demonstrates the timing of chemotherapy could have a significant impact on treatment for glioblastoma patients. Read More
Study shows how cholesterol becomes dysregulated in brain cancer cells and reports the gene responsible for the dysregulation could be a potential target to help treat glioblastoma brain cancer. Read More
Researchers have developed a Dp44mT nano-carrier that can directly target glioblastoma and other brain cancer cells. Read More
Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer. Read More
A new zebrafish model holds the potential for future studies of glioblastoma, an aggressive and lethal brain cancer. Read More
Study reveals a detailed map of gene proteins, infiltrating cells, and signaling pathways that play significant roles in the development and progression of glioblastoma brain cancer. Read More
Inhibiting the SCD enzyme and blocking the function of FOSB blunts acquired drug resistance and improves survival in mouse models of glioblastoma brain cancer. Read More
Researchers have identified a pathway involving a protein called Rab35 in glioblastoma brain cancer. The study reports restoring the activity of Rab35 could have therapeutic benefits for those with glioblastoma. Read More
20% of glioblastoma brain cancers are fueled by overactive mitochondria. Researchers say these cases may be treatable by drugs currently under trial. Read More
